Industry

A first-in-class investigational microbiome drug to treat recurrent Clostridium difficile infection

Bacthera in collaboration with Seres Therapeutics announced to manufacture SER-109, an investigational oral microbiome therapeutic to treat recurrent Clostridioides difficile infection (CDI).

Microbiome Connect: Gut Therapeutics Returns in Fresh Amsterdam Location

The Microbiome Connect: Gut Therapeutics Summit returns face to face on the 7-8 December. Join the list today whilst tickets are still available and don't forget to use MP10 to…

IPA EU & ISAPP: 4 science-based criteria to correctly qualify as a probiotic

20 years ago the world leading groups of experts FAO/WTO defined probiotics microorganisms in food and food supplements

Probiotics & Co: «Now’s the time to write the new “Rome criteria”»

New criteria for the probiotics of the future. We discussed it with Lorenzo Morelli (Catholic University of the Sacred Heart, Italy).

A gut microbiome protector for patients with hematologic malignancies

Dr. Christine Robin, the principal investigator at the Henri-Mondor Hospital (Creteil, France), said: “With all my team, we are glad to have recruited the first patient in MICROCARE.”

Food culture and gut health: a initiative to define the frame for consistent evidence

François Bourdichon presents the IDF's initiative of defining standards and putting a frame beyond probiotics.

Lallemand’s L. rhamnosus HA-114 supports during a weight management program

Brunella V. Gonzales Cautela (Lallemand) discusses the impact of L. rhamnosus HA-114 on a weight loss program for people suffering of obesity and overweight.

The IPA Track Day: take home message from the 11th Probiotics, Prebiotics & New foods Congress

Interview with George Paraskevakos, Executive Director at International Probiotics Association.

IPA Europe, regulatory, scientific and consumer perspective on probiotics

Several angles were raised, in Europe and Worldwide, during the 11th edition of the International Congress Probiotics, Prebiotics and New Foods.

Amandine Brochot – Akkermansia muciniphila: ‘How we developed the first next generation probiotic’

Amandine Brochot from A-Mansia Biotech tells us about the development of the first next-generation probiotic: Akkermansia muciniphila.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top